关注
Meera Mohan
Meera Mohan
在 mcw.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Inhibiting MEK in MAPK pathway-activated myeloma
CJ Heuck, Y Jethava, R Khan, F van Rhee, M Zangari, S Chavan, ...
Leukemia 30 (4), 976-980, 2016
1122016
Update on the optimal use of bortezomib in the treatment of multiple myeloma
M Mohan, A Matin, FE Davies
Cancer management and research, 51-63, 2017
722017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
M Mohan, A Buros, P Mathur, N Gokden, M Singh, S Susanibar, ...
American Journal of Hematology 92 (8), 739-745, 2017
502017
Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome
M Mohan, N Weinhold, C Schinke, S Thanedrarajan, L Rasche, ...
British Journal of Haematology 189 (1), 67-71, 2020
462020
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
MB Abid, M Rubin, N Ledeboer, A Szabo, W Longo, M Mohan, NN Shah, ...
Cancer Cell 40 (4), 340-342, 2022
392022
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
M Mohan, S Nagavally, B Dhakal, SV Radhakrishnan, S Chhabra, ...
Blood Advances 6 (8), 2466-2470, 2022
352022
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
C Schinke, EM Boyle, C Ashby, Y Wang, V Lyzogubov, C Wardell, P Qu, ...
Blood cancer journal 10 (6), 70, 2020
332020
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
C Schinke, A Hoering, H Wang, V Carlton, S Thanandrarajan, ...
Haematologica 102 (8), e313, 2017
282017
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study
J Dong, Z Garacci, CS Buradagunta, A D’Souza, M Mohan, ...
Blood Cancer Journal 12 (2), 34, 2022
272022
Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma
M Mohan, R Chakraborty, S Bal, A Nellore, M Baljevic, A D'Souza, ...
British Journal of Haematology 203 (5), 736-746, 2023
232023
Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma
LR Hammons, A Szabo, A Janardan, B Dhakal, S Chhabra, A D’Souza, ...
JAMA Network Open 5 (10), e2238961-e2238961, 2022
222022
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
M Mohan, S Kendrick, A Szabo, N Yarlagadda, D Atwal, Y Pandey, A Roy, ...
Blood Advances 6 (3), 808-817, 2022
202022
Salvage second transplantation in relapsed multiple myeloma
B Dhakal, A D’Souza, A Kleman, S Chhabra, M Mohan, P Hari
Leukemia 35 (4), 1214-1217, 2021
202021
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
S Al Hadidi, A Szabo, J Esselmann, L Hammons, M Hussain, ...
Bone Marrow Transplantation 58 (4), 443-445, 2023
172023
Immunotherapy in multiple myeloma—Time for a second major paradigm shift
M Mohan, P Hari, B Dhakal
JCO Oncology Practice 17 (7), 405-413, 2021
172021
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
L Hammons, A Szabo, A Janardan, V Bhatlapenumarthi, E Annyapu, ...
Haematologica 109 (3), 906, 2024
152024
Belantamab in combination with dexamethasone in patients with triple-class relapsed/refractory multiple myeloma
T Atieh, S Atrash, M Mohan, L Shune, Z Mahmoudjafari, J Quick, J Riffel, ...
Blood 138, 1642, 2021
132021
Two Cases of Vancomycin-Resistant Enterococcus faecium Bacteremia With Development of Daptomycin-Resistant Phenotype and its Detection Using Oxford …
Z Udaondo, P Jenjaroenpun, T Wongsurawat, E Meyers, C Anderson, ...
Open Forum Infectious Diseases 7 (6), ofaa180, 2020
132020
Salvage autologous stem cell transplantation in daratumumab-refractory multiple myeloma
L Yarlagadda, S Gundarlapalli, R Parikh, RD Landes, M Kottarathara, ...
Cancers 13 (16), 4019, 2021
122021
Extensive remineralization of large pelvic lytic lesions following total therapy treatment in patients with multiple myeloma
M Mohan, RS Samant, D Yoon, AF Buros, A Branca, CO Montgomery, ...
Journal of Bone and Mineral Research 32 (6), 1261-1266, 2017
122017
系统目前无法执行此操作,请稍后再试。
文章 1–20